ProPhase Labs Files 8-K on Financials
Ticker: PRPH · Form: 8-K · Filed: Aug 13, 2025 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
ProPhase Labs dropped an 8-K detailing financial results and operations.
AI Summary
ProPhase Labs, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Uniondale, New York.
Why It Matters
This 8-K filing provides investors with crucial updates on ProPhase Labs' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial condition and results of operations, with no immediate indication of significant new risks.
Key Numbers
- 000-21617 — SEC File Number (Identifies the company's filing with the SEC.)
- 23-2577138 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- ProPhase Labs, Inc. (company) — Filer
- August 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Uniondale, New York (location) — Address of principal executive offices
- QUIGLEY CORP (company) — Former company name
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it reports on 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that the company is making public disclosures to prevent selective disclosure of material non-public information.
When was ProPhase Labs, Inc. incorporated?
The company was incorporated in Delaware.
What was the former name of ProPhase Labs, Inc.?
The former company name was QUIGLEY CORP, with a date of name change on March 28, 1993.
What is the primary business address of ProPhase Labs, Inc.?
The principal executive offices are located at 626 RXR Plaza, 6th Floor, Uniondale, New York 11556.
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2025-08-13 09:00:29
Key Financial Figures
- $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indic
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 135KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001641172-25-023344.txt ( ) — 362KB
- prph-20250813.xsd (EX-101.SCH) — 3KB
- prph-20250813_lab.xml (EX-101.LAB) — 33KB
- prph-20250813_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 PROPHASE LABS, INC. (Exact name of Company as specified in its charter) Delaware 000-21617 23-2577138 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 626 RXR Plaza , 6th Floor Uniondale , New York 11556 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (516) 989-0763 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operation and Financial Condition. On August 13, 2025, ProPhase Labs, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 7.01 Regulation FD Disclosure. As previously announced, the Company will conduct a conference call today, Wednesday, August 13, 2025, at 2:00 p.m. (Eastern Time) to discuss its financial results and provide an update on corporate developments. The information contained in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K other than statements of historical fact are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the Company's ability to regain compliance with Nasdaq listing standards or receive additional time from Nasdaq to regain compliance if necessary. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and the negative of such terms or other similar expressions may identify forward-looking based on the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Item 9.01 Financial Statements and Exhibits. (d) Exhibits No. Description 99.1 Press Release dated August 13, 2025, ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 104 Cover Page Interactive Da